CBP Rulings
Index coverage and update dates
- Indexed
- 6,578 rulings
- NY rulings from
- Nov 2024
- Newest here
- Nov 12, 2026
- Newest on CBP
- Nov 13, 2026
- Customs Bulletin through
- Nov 18, 2026
- Last sync with CBP
- 1 hour ago
- NY N363467Aug 17, 2026
The tariff classification of ZIEXTENZO® (pegfilgrastim-bmez) Injection in dosage form, from Austria
In your letter dated July 21, 2026, you requested a tariff classification ruling. ZIEXTENZO (pegfilgrastim-bmez), imported in 6 mg/0.6 mL prefilled syringes, is a leukocyte growth factor biosimilar to Neulasta®. It is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
- NY N350948Dec 18, 2025
The tariff classification of HEC88473 Drug Product (also known as APL-18881) in dosage form, from China
In your letter dated July 4, 2025, you requested a tariff classification ruling. We apologize for the delay as the information was submitted to our laboratory for analysis. HEC88473 (also known as APL-18881) is a biological bi-specific protein targeting glucagon-like peptide-1 (GLP-1) and fibroblast growth factors 21 (FGF21). It is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and Alcohol Use Disorder (AUD).
- NY N351298Aug 12, 2025
The tariff classification of Lentiviral Vector from China
In your letter dated July 14, 2025, you requested a tariff classification ruling. Lentiviral vector is derived from a HIV-1 lentivirus that has been modified by removal of viral replication genes including deletions that result in a self-inactivating lentiviral vector. The lentiviral vector is produced in a HEK293T cell line and purified from the HEK293T cells using multiple different biomanufacturing techniques and is sterile filtered. The lentiviral vector is formulated in a salt-based solution and is frozen at -80°C for long-term storage and shipment.
Source: rulings.cbp.gov (CROSS). This index holds New York rulings issued since Nov 2024 and the Headquarters rulings they cite. It is not the full CROSS database of 222,467 rulings, and it does not hold every Headquarters ruling. New rulings usually appear here within a few days of CBP publishing them; a ruling published long after its number was assigned can take several weeks. Revoked, modified and proposed marks come from the weekly Customs Bulletin, where CBP publishes most such actions under 19 U.S.C. 1625(c), read here from the Nov 2024 issues onward, and from the subjects of indexed Headquarters rulings. A revocation is marked from the date it takes effect. The absence of a mark is not confirmation that a ruling is still in effect. A ruling letter is binding on CBP only for the particular transaction or issue it describes (19 CFR 177.9). Confirm the text and status on CROSS before relying on a ruling. Not legal advice.